To investigate maternal adverse effects and perinatal and neonatal outcomes of women receiving coronavirus disease-2019 (COVID-19) vaccination during pregnancy. Seven hundred and sixty pregnant women who were followed up in obstetrics outpatients were included in this prospective cohort study. COVID-19 vaccination and infection histories of the patients were recorded. Demographic data, including age, parity, and presence of systemic disease and adverse events following COVID-19 vaccination were recorded. Vaccinated pregnant women were compared with unvaccinated women in terms of adverse perinatal and neonatal outcomes. Among the 760 pregnant women who met study criteria, the data of 425 pregnant women were analyzed. Among these, 55 (13%) were unvaccinated, 134 (31%) were vaccinated before pregnancy, and 236 (56%) pregnant women were vaccinated during pregnancy. Of those who were vaccinated, 307 patients (83%) received BioNTech, 52 patients (14%) received CoronaVac, and 11 patients (3%) received both CoronaVac and BioNTech. The local and systemic adverse effect profiles of patients who received COVID-19 vaccination either before or during pregnancy were similar (p=0.159), and the most common adverse effect was injection site pain. COVID-19 vaccination during pregnancy did not increase the ratio of abortion (24 wk), preeclampsia, gestational diabetes mellitus, fetal growth restriction, second-trimester soft marker incidence, time of delivery, birth weight, preterm birth (<37 wk) or admission to the neonatal intensive care unit compared to the women who were not vaccinated during pregnacy. COVID-19 vaccination during pregnancy did not increase maternal local and systemic adverse effects or poor perinatal and neonatal outcomes. Therefore, regarding the increased risk of morbidity and mortality related to COVID-19 in pregnant women, the authors propose that COVID-19 vaccination should be offered to all pregnant women.

We aimed to review the corpus callosum agenesis (CCA) cases diagnosed and managed in our University to contribute to the literature about this antenatally diagnosed fetal cranial anomaly by revealing the antenatal and postnatal outcomes of CCA. This retrospective and cross-sectional study examined CCA detected in our clinic between 2012 and 2021. Genetic results, accompanying additional anomalies, termination, and perinatal mortality rates were also calculated. Neurodevelopmental outcomes were revealed by investigating motor development, cognitive development, behavioral disorder, speech delay, personal-social backwardness, and epilepsy in cases of isolated CCA and non-isolated CCA in the postnatal period. Data from 30 fetuses were evaluated during the study. The number of isolated CCA and non-isolated CCA cases is 11 (37.5%) and 19 (62.5%), respectively, and the number of partial CCA and complete CCA cases is 8 (26%) and 22 (74%), respectively. Among the 30 fetuses, the numbers of live births, chromosomal anomalies, perinatal mortalities, and terminations were found to be 14 (47%), 3 (10%), 3 (10%), and 13 (43%), respectively. Postnatal evaluation was performed in 14 children, and normal neurodevelopmental outcomes were observed in 5 (35.7%). All these children were from the isolated CCA group. Additionally, poor neurodevelopmental outcome was detected in 37.5% of isolated CCA. If CCA is detected in the fetus, additional ultrasonographic anomaly and genetic examination should be performed to differentiate isolated CCA from non-isolated CCA. While the termination option can be offered to the family by informing them about poor pregnancy outcomes in non-isolated CCA, counseling in isolated CCA remains contradictory, and more comprehensive prospective studies are needed. This study was retrospectively registered and authorized by the local Ethics Committee of Ankara University (clinical trial date 06.06.2024/ number 1391402).

OBJECTIVE: Aberrant right subclavian artery, which is detected in 1-1.5% of the population, is considered an anatomical variant. Aberrant right subclavian artery is usually not symptomatic, but can sometimes lead to dysphagia due to esophageal compression. On the other hand, it has been found that it has accompanied some fetal anomalies in the last two decades. Although aberrant right subclavian artery is seen at a rate of 1-1.5% in normal chromosomal fetuses, it is seen at a rate of 19-36%, especially in fetuses with Down syndrome. STUDY DESIGN: Our study was carried out in the Department of Obstetrics and Gynaecology at Ankara University Faculty of Medicine between the dates of January 2017-January 2020. Pregnant women have had their detailed ultrasonography at our clinic and who were between 18th-24th gestational weeks were included. Amniocentesis was performed on the patients who have accepted, and genetic results were followed up. The patients who did not accept were followed up until after birth, and genetic testing was requested for babies suggestive of anomaly. RESULTS: Our study included 6205 patients who underwent detailed ultrasonography in our clinic between January 2017 and June 2020. Our detailed ultrasonography application week was between 16-24 weeks. During this period, aberrant right subclavian artery was detected in 47 of our patients. The detection rate of ARSA in the normal population in our study was 0.7% (46/6205). While aberrant right subclavian artery was the only ultrasonographic finding in 28 patients, extra anomalies were observed in 18 patients. Down syndrome was detected in four fetuses, CONCLUSION: We did not find any chromosomal anomalies in any of the patients with isolated aberrant right subclavian artery. Therefore, we do not recommend invasive intervention in patients with isolated aberrant right subclavian artery. On the other hand, our study confirmed that aberrant right subclavian artery screening should be a part of a detailed fetal ultrasonographic examination. Further studies with larger patient groups are needed.

This study aimed to evaluate the perinatal outcomes of isolated single umbilical artery (iSUA) and incidence of fetuses diagnosed with Single Umbilical Artery (SUA) in the second trimester. We retrospectively analyzed the data of 40,800 pregnant women who had undergone detailed ultrasonography between September 2011 and September 2021 in the perinatology clinic of tertiary university hospital. Those diagnosed with SUA accompanied by structural and genetic anomalies and maternal diseases among the 402 cases and multiple pregnancies were excluded from the study. The remaining 307 iSUA cases were compared with 650 randomly selected cases Double Umbilical Artery (DUA) by need for cesarean section due to fetal distress or suspicious Non-Stress Test (NST), delivery frequency before 37 and 34 weeks, birth weight, fetal gender, oligohydramnios, small for gestational age (SGA; <10% percentile birth weight)), intrauterine fetal death (IUFD), Apgar scores, and admission to a neonatal intensive care unit (NICU) for antenatal and perinatal outcomes. A total of 402 (0.9%) cases were diagnosed with SUA. Thirty-nine (9.7%) cases had structural anomalies, and 13 (3.2%) had genetic anomalies. While the most frequently detected chromosomal disorder was trisomy 18, central nervous system (CNS) and cardiovascular system (CVS) anomalies were the most prevalent accompanying structural anomalies. Comparing 307 cases with iSUA with 650 cases with DUA, we detected that the group with iSUA yielded significantly lower Apgar scores at 1 st and 5th minutes, lower birth weight, SGA prevalence, higher cesarean section need due to fetal distress and unreliable non-stress test, higher IUFD, and higher preterm birth. Overall, we believe that the patients need to be recruited for a detailed ultrasonographic examination, as well as CNS and CVS examinations, following the diagnosis of SUA and that interventional diagnostic tests need to be applied to those with structural anomalies. Although genetic diagnostic tests are not required among iSUA cases, we found that cases with iSUA had higher IUFD in the second trimester, premature birth, low birth weight, and need for cesarean section.

The omphalocele-exstrophy vesicalis-imperforated anus-spinal defects (OEIS) complex is a rare variant of the bladder exstrophy epispadias complex and multisystem anomalies involving the gastrointestinal, genitourinary, and skeletal systems. The number of patients who have OEIS complex and do not terminate their pregnancy is small. We present the prenatal and postnatal radiological images of a patient diagnosed with OEIS at the twentieth gestational week.